sales@jinjingroup.com

  News Introduction

3,4-Dihydroxybenzaldehyde(cas 139-85-5) standards and scientific

Date : 2016/8/23 11:56:48

3,4-Dihydroxybenzaldehyde(cas 139-85-5) is one of the chemical composition in Chinese medicine. From the classical side or from the modern clinical medicine prescription, in addition to considering herbs Pieces factors, such subtraction Smell or compatibility changes affect the safety and efficacy of drugs, medicines will also affect the quality standards. This is the choice of the material composition and efficacy related to qualitative and quantitative determination and the establishment of quality standards. Analysis by reading "Chinese Pharmacopoeia" 2010 edition and the 2015 edition of a found three problems difficult for listed product quality control:

(1) the quality of raw materials and medicines relevance, proprietary formulation containing the active ingredient and the amount of the medicine (Pieces) or extract is not equipped.

(2) According to the principles of traditional Chinese medicine compound compatibility, different medicines in the same position in different formulations, some formulation chosen quantitative indicators contrary to the principle of compatibility, use only the determination of the chemical composition(such as 3,4-dihydroxybenzaldehyde(cas 139-85-5)) of good quantitative control. As in a number of formulations, regardless of the status of peony in the prescription, with red peony or peony, are made of the amount of paeoniflorin as quality control indicators; even a "make" multi-drug compound in the composition of the herb licorice ingredient an amount as a quality control targets. Some simply will not "Jun" medicine ingredient as Quality Control.

Quality and comparability of substitutability (3) of the same name varieties. In the "Chinese Pharmacopoeia" was found in the same prescription compound preparation made of different formulations of the product, at the same dose, route of administration the same, having substitutability between different forms of the same name drugs. But because of proprietary Chinese medicines containing different formulations of the same name varieties, since the standards set consistent, quality control indicators inconsistent, difficult to explain the substitutability between different forms. "Chinese Pharmacopoeia" 2015 version there are three or more forms of the same name medicine 63, forming a 222 varieties. Quite a lot of different forms of the same name cultivars qualitative identification and quantitative determination of the number of components and there is a big difference between the quantitative determination of indicators.